@entity519 is a common feature of solid @entity5 and an important contributor to anti- @entity5 drug resistance. @entity519 inducible factor-1 (HIF-1) is one of the key mediators of the @entity519 signaling pathway, and was recently proven to be required for @entity2857 resistance in hepatocarcinoma (HCC). MicroRNAs have emerged as important posttranslational regulators in HCC. It was reported that miR-338-3p levels are associated with clinical @entity146 of HCC. However, the roles of miR-338-3p in @entity66 and resistance to its therapeutic drugs are unknown. In this study, we found that miR-338-3p was frequently down-regulated in 14 HCC clinical samples and five cell lines. Overexpression of miR-338-3p inhibited @entity1965 3'-UTR luciferase activity and @entity1965 protein levels in HepG2, SMMC-7721, and Huh7 cells. miR-338-3p significantly reduced cell viability and induced cell apoptosis of HCC cells. Additionally, @entity1965 overexpression rescued and @entity1965 knock-down abrogated the anti-HCC activity of miR-338-3p. Furthermore, miR-338-3p sensitized HCC cells to @entity2857 in vitro and in a HCC subcutaneous @entity19 @entity5 model by inhibiting @entity1965 . Collectively, miR-338-3p inhibits @entity5 growth and sensitizes HCC cells to @entity2857 by down-regulating @entity1965 . Our data indicate that miR-338-3p could be a potential candidate for HCC therapeutics.

MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to XXXX by Targeting @entity519 -Induced Factor 1a.

@entity66 :: ('MESH:D004194', 'Disease') :: ['HCC disease'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressiveness'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'HCC tumor'] @entity19 :: ('10090', 'Species') :: ['nude mice'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity519 :: ('MESH:D000860', 'Disease') :: ['Hypoxia', 'hypoxia'] @entity1965 :: ('15251(Tax:10090)', 'Gene') :: ['HIF-1a']
@entity2857 :: (MESH:C471405,Chemical) :: ['Sorafenib']
